Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) and CryoPort (NASDAQ:CYRX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Pacific Biosciences of California and CryoPort, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pacific Biosciences of California | 2 | 3 | 0 | 0 | 1.60 |
| CryoPort | 0 | 2 | 7 | 0 | 2.78 |
Pacific Biosciences of California currently has a consensus target price of $2.57, indicating a potential upside of 30.95%. CryoPort has a consensus target price of $21.69, indicating a potential upside of 9.04%. Given Pacific Biosciences of California’s higher possible upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than CryoPort.
Earnings & Valuation
This table compares Pacific Biosciences of California and CryoPort”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pacific Biosciences of California | $160.01 million | 3.83 | -$546.38 million | ($0.42) | -4.67 |
| CryoPort | $176.18 million | 5.72 | $78.30 million | ($0.97) | -20.51 |
CryoPort has higher revenue and earnings than Pacific Biosciences of California. CryoPort is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Pacific Biosciences of California and CryoPort’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pacific Biosciences of California | -81.31% | -5,752.12% | -19.52% |
| CryoPort | -21.46% | -8.28% | -4.88% |
Risk and Volatility
Pacific Biosciences of California has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.
Institutional and Insider Ownership
92.9% of CryoPort shares are owned by institutional investors. 3.7% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
CryoPort beats Pacific Biosciences of California on 10 of the 14 factors compared between the two stocks.
About Pacific Biosciences of California
Pacific Biosciences of California, or PacBio, develops and sells DNA sequencing systems and related products for life science research and clinical applications. The company is known for its single-molecule real-time (SMRT) sequencing technology, which produces long reads that can help researchers study complex regions of the genome and identify genetic variations. Its portfolio includes HiFi sequencing systems such as the Revio and Vega platforms, along with instruments, consumables, software and services used to prepare, sequence and analyze genetic samples.
About CryoPort
Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
